Intervention

Islatravir

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting0

Common conditions8

Lead sponsors shown1

Clinical trials

8 shown

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)NCT05115838 · 2024-01-04

A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)NCT05130086 · 2022-10-17

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]NCT04564547 · 2021-03-09

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)NCT04644029 · 2021-02-24

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)NCT04515641 · 2020-11-05

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)NCT04303156 · 2020-06-18

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)NCT04003103 · 2019-09-19

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)NCT03272347 · 2017-11-27

Common conditions

HIV-1 Infection3 Human Immunodeficiency Virus (HIV) Infection2 HIV1 HIV-I1 Human Immunodeficiency Virus1 Human Immunodeficiency Virus (HIV) Infections1 Human Immunodeficiency Virus Type 11 Prophylaxis1

Leading sponsors

Merck Sharp & Dohme LLC8

Trial status mix

COMPLETED5

WITHDRAWN2

TERMINATED1

Phase mix

PHASE25

PHASE12

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.